I'm sure this bears closer scrutiny, but:
I'm sure this bears closer scrutiny, but:
The underlying notion in both bills, however, has also been criticized over concerns that, by extending data exclusivity beyond the existing timeframes, the law could slow the introduction of lower-cost generic versions of many drugs. Consequently, prices would remain higher, an issue that Express Scripts chief medical officer Steve Miller raised at a congressional hearing last year.
I'm sorry. Is this the same industry (generic drug manufacturers) that has raised its prices so much in the last 2-5 years (hey, we're the only ones making this anymore, whoopee!) that there was a Congressional hearing about it last month?
http://blogs.wsj.com/pharmalot/2014/12/15/senate-bill-offers-15-years-of-data-exclusivity-for-drugs-for-unmet-needs/
http://blogs.wsj.com/pharmalot/2014/12/15/senate-bill-offers-15-years-of-data-exclusivity-for-drugs-for-unmet-needs
The underlying notion in both bills, however, has also been criticized over concerns that, by extending data exclusivity beyond the existing timeframes, the law could slow the introduction of lower-cost generic versions of many drugs. Consequently, prices would remain higher, an issue that Express Scripts chief medical officer Steve Miller raised at a congressional hearing last year.
I'm sorry. Is this the same industry (generic drug manufacturers) that has raised its prices so much in the last 2-5 years (hey, we're the only ones making this anymore, whoopee!) that there was a Congressional hearing about it last month?
http://blogs.wsj.com/pharmalot/2014/12/15/senate-bill-offers-15-years-of-data-exclusivity-for-drugs-for-unmet-needs/
http://blogs.wsj.com/pharmalot/2014/12/15/senate-bill-offers-15-years-of-data-exclusivity-for-drugs-for-unmet-needs
Comments
Post a Comment